Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Change in Receivables (2020 - 2025)

Maxcyte (MXCT) has disclosed Change in Receivables for 6 consecutive years, with -$4.8 million as the latest value for Q4 2025.

  • Quarterly Change in Receivables fell 4031.97% to -$4.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.1 million through Dec 2025, up 6.36% year-over-year, with the annual reading at -$1.1 million for FY2025, 6.36% up from the prior year.
  • Change in Receivables for Q4 2025 was -$4.8 million at Maxcyte, down from $2.6 million in the prior quarter.
  • The five-year high for Change in Receivables was $4.0 million in Q4 2022, with the low at -$4.8 million in Q4 2025.
  • Average Change in Receivables over 5 years is -$66295.0, with a median of $180000.0 recorded in 2024.
  • The sharpest move saw Change in Receivables surged 46455.56% in 2023, then tumbled 4031.97% in 2025.
  • Over 5 years, Change in Receivables stood at $918900.0 in 2021, then surged by 336.63% to $4.0 million in 2022, then tumbled by 141.25% to -$1.7 million in 2023, then skyrocketed by 107.37% to $122000.0 in 2024, then crashed by 4031.97% to -$4.8 million in 2025.
  • According to Business Quant data, Change in Receivables over the past three periods came in at -$4.8 million, $2.6 million, and $238000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.